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Objective: To estimate the difference in use of
hospital resources in the Finnish Colorectal Cancer
(CRC) screening programme between those invited and
controls, within the year of randomisation and the next
year.
Design: CRC screening was implemented in Finland in
2004 as a population-based randomised design using
biennial faecal occult blood test (FOBT) for men and
women aged 60–69 years. Those randomised to
screening and control groups during years 2004–2009
were included in this analysis and use of hospital
resources was estimated. Data were collected from the
national register on hospital discharges. Outpatient
visits, inpatient episodes and colonoscopies were
compared between the two groups.
Results: The screening group comprised of 123 149
and control group of 122 930 people. Most people in
both groups had not used hospital resources at all.
More people in the screening group than in the control
group had at least one hospital-based outpatient visit
(7.8% vs 7.4%), inpatient episode (3.9% vs 3.8%) and
colonoscopy (1.5% vs 1.3%). In total, the screening
group had 31 975 and control group 27 061
cumulative outpatient visits, 9260 and 7903 inpatient
episodes, and 2686 and 1756 hospital colonoscopies,
respectively. The proportion of those with a positive
FOBT result with at least one outpatient visit, one
inpatient episode or one colonoscopy, was 3.7 times,
2.5 times or 9 times that of those with a negative FOBT
result, respectively.
Conclusions: CRC screening using the FOBT slightly
increased the volume of hospital outpatient visits,
inpatient episodes and hospital colonoscopies in
Finland.
INTRODUCTION
Colorectal cancer is the third most common
cancer, following breast and prostate cancers,
and the second most common cause of
cancer deaths after lung cancer, in Europe,
including in Finland. Within the 27 Member
states of the European Union, 340 000
people were diagnosed with colorectal
cancer in 2012 and about 150 000 people
died because of it.1 Among 5.4 million Finns,
the corresponding ﬁgures are approximately
2500 people diagnosed with colorectal
cancer and more than 1000 deaths every
year. The incidence of colorectal cancer
increased for decades while mortality was
stable among men and decreased among
women since the 1970s.2 3
Colorectal cancer screening aims to reduce
the mortality of the disease by discovering
the cancer at an early, asymptomatic stage, to
enable more effective and less invasive treat-
ment. Screening with a faecal occult blood
test (FOBT) has been shown to reduce mor-
tality from colorectal cancer in a number of
randomised screening studies.4–7 In a
Cochrane review,8 the combined results of
these studies showed a 16% reduction in the
relative risk of colorectal cancer mortality.
Summary box
What is already known about this subject?
▸ According to randomised trials, Colorectal
Cancer (CRC) screening with the guaiac-based
faecal occult blood test (FOBT) reduces
CRC-related mortality.
▸ Based on the available evidence, the EU recom-
mends CRC screening.
▸ Evidence on the impact of guaiac-based FOBT
screening on resource use is missing.
What are the new findings?
▸ Our study showed a slight increase in the use of
hospital services (outpatient visits, inpatient epi-
sodes and colonoscopies) in the screening
group compared to the control group.
▸ People who were invited to screening but who
did not attend were more likely to use hospital
resources for gastrointestinal reasons than
people with a negative FOBT result.
How might it impact on clinical practice in
the foreseeable future?
▸ This study only evaluates the resource use on a
hospital level and not the impact of screening
on primary healthcare services.
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Three of these studies4 6 7 used biennial screening and
showed an average of 15% relative risk reduction in colo-
rectal cancer mortality. The reduction in mortality was
seen in all three trials even though there was large vari-
ation in the design, such as the age of the target popula-
tion, screening intervals, attendance rate and length of
follow-up. Also, the cost-effectiveness of colorectal
cancer screening has been modelled in a number of
studies, in various countries, using different screening
tests and strategies.9–15 Based on the available evidence,
the Council of the European Union already, in 2003,
recommended the implementation of a population-
based screening programme for colorectal cancer to the
EU Member States.16
In Finland, colorectal cancer screening started in 2004
as a population-based randomised study. The idea was to
launch a new screening programme in such a way that it
can be reliably evaluated. The target population of
screening is men and women aged 60–69 years, based on
the fact that the incidence of and mortality from colorec-
tal cancer increase after 60 years of age.3 The municipal-
ities responsible for providing health services in Finland
can voluntarily join the programme, and the number of
piloting municipalities has increased from 22 (of 444) in
2004 to 153 (of 336) in 2012. The target population in
these municipalities was randomised at an individual
level within municipality, birth year and in sex speciﬁc
blocks, to screening and control groups. Owing to the
gradual expansion of the programme as a randomised
health services study,17 the effects of the ultimate national
screening programme on the allocation of health care
resources can be evaluated as a part of routine health
service.
The aim of this article was to estimate the difference
in the use of hospital resources between those invited
and the controls in the Finnish colorectal cancer screen-
ing programme within the ﬁrst screening round.
MATERIALS AND METHODS
When the Finnish colorectal cancer screening study was
launched, a national screening centre was established in
the city of Tampere, at the local cancer society, to deal
with the invitations, responses and recommendations for
referrals, and to analyse the faecal samples. FOBT kits
(Hemoccult; Beckman Coulter, USA) are posted to those
offered screening along with a letter of invitation to par-
ticipate in the programme and advice on how to take the
sample. The kits are also returned by post. If any traces of
blood are found in the sample, the person is referred to a
contact nurse in their home municipality, for further
examinations. Diagnostic conﬁrmation, treatment and
follow-up of people who screened positive are conducted
within the normal health services at the local level and
are paid for mostly by the home municipality of the par-
ticipant being screened. Those in the control arm are
identiﬁed but not contacted. The control population
receives routine health services available in Finland.18
All individuals (n=246 079) who were randomised to
the colorectal cancer screening (n=123 149) or control
(n=122 930) groups during years 2004–2009 were identi-
ﬁed and their data on healthcare resource use were
gathered from the Finnish Hospital Discharge Register
(FHDR). The follow-up of each individual was from the
beginning of the year of randomisation up to the end of
the next calendar year (two full years). The study period
was 2004–2010.
For those randomised during the years 2004–2009,
healthcare utilisation data on all gastrointestinal-related
hospital-based outpatient visits and inpatient episodes of
care were gathered on the year of randomisation and
the following year. The data were restricted by ICD-10
codes that were related to gastrointestinal symptoms:
C15-C26; D12 and K00-K93. Colonoscopies performed
during those visits and episodes in hospitals were also
examined, including procedure codes UJF32, UJF34 and
UJF45. Colonoscopies performed in primary healthcare
(including the screening colonoscopies) are not
included in the analysis for either the screening or the
control group. See table 1 for the explanation of the
codes used in this article.
The FHDR is one of the oldest individual level hos-
pital discharge registers covering an entire country. The
FHDR has total (legislative) coverage of all inpatient
care provided at university, general and psychiatric hos-
pitals or primary care health centres, as well as treat-
ment in military and prison wards and private hospitals,
since 1969. Each record contains data on several vari-
ables, such as personal identity number, age at admis-
sion, gender, hospital identiﬁer code, admission and
discharge dates, reason for admission (ICD-10 code
since 1996), and diagnostic and treatment activities. The
register includes data on clinical procedures from 1986
onwards and the current coding system for procedures
has been in use since 2004. The data on hospital out-
patient visits have been collected since 1998 with some
limitations and they are considered to be comparable
from 2006 onwards. The completeness and accuracy of
the FHDR has been reviewed to be good. Data on out-
patient services at the primary care level (general practi-
tioner visits, etc) are available from 1994 onwards at
aggregate level.19 20
The percentage of people in the target population
who used hospital services and the cumulative number
of outpatient visits, hospital inpatient episodes and hos-
pital colonoscopies, were calculated. We compared those
randomised to screening to those in the control group.
The screening group was also divided according to
uptake of screening and test result. The differences
between the arms in distributions of the individual vari-
ables were tested for statistical signiﬁcance by the χ2 test.
RESULTS
The study population included 246 079 people, 123 149
(50%) in the screening group and 122 930 in the
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control group. Based on the randomised setting of the
study, the groups were similar in demographic
characteristics.
By 2009, the programme covered about 40% of the
ultimate target population and 20% were invited to
screening. The attendance rate within the ﬁrst screening
round was 68% during the years 2004–2009, with some
variation by calendar year. During these years, 2944 indi-
viduals (2.4%) had a positive FOBT (table 2).
The number and proportion of people who had at
least one gastrointestinal-related hospital outpatient visit,
inpatient episode or colonoscopy during the year of ran-
domisation or the next year, is presented in table 3.
Most of the study population in both screening and
control groups had not had any gastrointestinal-related
hospital outpatient visits or inpatient episodes within the
2 years following randomisation. The proportion of
people with at least one outpatient visit, inpatient
episode or colonoscopy, was higher in the screening
group than in the control group, for all the types of
resource use evaluated. The difference between the
groups was the largest in outpatient visits: there were 523
Table 1 Explanation of the diagnose and procedure codes used in the article
ICD-10 codes C15-C26 Malignant neoplasms of digestive organs
C15 Malignant neoplasm of oesophagus
C16 Malignant neoplasm of stomach
C17 Malignant neoplasm of small intestine
C18 Malignant neoplasm of colon
C19 Malignant neoplasm of rectosigmoid junction
C20 Malignant neoplasm of rectum
C21 Malignant neoplasm of anus and anal canal
C22 Malignant neoplasm of liver and intrahepatic bile ducts
C23 Malignant neoplasm of gall bladder
C24 Malignant neoplasm of other and unspecified parts of biliary tract
C25 Malignant neoplasm of pancreas
C26 Malignant neoplasm of other ill-defined digestive organs
D12 Benign neoplasm of colon, rectum, anus and anal canal
K00-K93 Diseases of the digestive system
K00-K14 Diseases of oral cavity, salivary glands and jaws
K20-K31 Diseases of oesophagus, stomach and duodenum
K35-K38 Diseases of appendix
K40-K46 Hernia
K50-K52 Non-infective enteritis and colitis
K55-K63 Other diseases of intestines
K65-K67 Diseases of peritoneum
K70-K77 Diseases of liver
K80-K87 Disorders of gallbladder, biliary tract and pancreas
K90-K93 Other diseases of the digestive system
National procedure codes* UJF32 Colonoscopy
UJF34 Left colonoscopy
UJF45 Flexible sigmoidoscopy with biopsy
*Based on the Nordic Classification of Surgical Procedures.
Table 2 Number and percentage of individuals in the Finnish Colorectal Cancer Screening programme by year of invitation,
arm and screening test result
Year of invitation





n Per cent n Per cent n Per cent n n
2004 109 2.4 3283 72.3 1149 25.3 4539 4539
2005 542 2.3 16 709 70.9 6311 26.8 23 562 23 565
2006 585 2.3 16 625 66.8 7687 30.9 24 897 24 898
2007 513 2.4 14 303 66.2 6778 31.4 21 594 21 375
2008 576 2.4 14 756 60.9 8899 36.7 24 231 24 229
2009 621 2.6 15 299 62.9 8406 34.6 24 326 24 324
Total 2944 2.4 80 975 65.8 39 230 31.9 123 149 122 930
Mäklin S, Hakama M, Rissanen P, et al. BMJ Open Gastro 2015;2:e000063. doi:10.1136/bmjgast-2015-000063 3
Open Access
people more in the screening group than in the control
group with at least one gastrointestinal-related outpatient
visit. The corresponding ﬁgures for people with at least
one inpatient episode or hospital-based colonoscopy
were 132 and 315, respectively. The people in the
screening group were more likely to undergo more col-
onoscopies per person than those in the control group
(ﬁgure 1).
A positive FOBT result increased the probability of
using hospital resources. After a positive test result, a
quarter of the people had at least one outpatient visit,
while 93% of those with a negative test result had no
outpatient visits at all. Also, the probability of undergo-
ing colonoscopy while in hospital was 9.6 times higher
in those with a positive test result compared to those
with a negative test result. Furthermore, those who were
invited to screening but did not attend were more likely
to use hospital resources for gastrointestinal reasons
than those with a negative FOBT result (table 3).
On average, 2.4% of the screening population had
only one outpatient visit and 5.5% had two visits or
more. The corresponding numbers for the control arm
were 3.9% and 3.5%, respectively. Maximum number of
visits per person was 86 in the screening group and 141
in the control group.
The cumulative number of outpatient visits, inpatient
episodes and hospital colonoscopies over the whole study
period is consistently higher in the screening arm than in
the control arm (table 4). The difference between the
arms was largest in the number of hospital colonoscopies:
there were 53% more colonoscopies performed per indi-
vidual in the screening group than in the control group.
For the outpatient visits and inpatient episodes, the
number of events was 18% and 17% higher, respectively,
in the screening group compared to the control group.
DISCUSSION
According to this study, the vast majority of the study
population, that is, 60–69-year-old Finnish men and
women, had not used hospital resources at all for any
gastrointestinal-related reasons. Slightly more people
in the screening group than in the control group had
at least one hospital-based outpatient visit (7.8% vs
7.4%) or inpatient episode (3.9% vs 3.8%). In total,
the screening group had 4914 more cumulative
outpatient visits and 1357 more inpatient episodes
than the control group. The proportions of test-
positive people with at least one outpatient visit
(26.0% vs 7.0%) or with at least one inpatient episode
(8.3% vs 3.3%) were clearly higher than those of
people with a negative FOBT result.
The difference in use of hospital resources between
the screening and control group is reliably comparable.
The setting of the Finnish colorectal cancer screening
programme makes it possible to evaluate the feasibility
and effectiveness of screening in a randomised, yet real-
world healthcare setting. Any possible systematic errors
within the Finnish Hospital Discharge registry will be
equally present in both groups.
Table 3 Number and proportion of individuals with at least one event (outpatient visit, inpatient episode and colonoscopy)




Total Control p ValuePositive test result Negative test result Non-attender
Number of individuals 2944 80 975 39 230 123 149 122 930
Outpatient visits*
N 764 5705 3190 9659 9136 <0.001
Per cent 26.0 7.0 8.1 7.8 7.4
Inpatient episodes*
N 243 2690 1911 4844 4712 <0.001
Per cent 8.3 3.3 4.9 3.9 3.8
Colonoscopies
N 339 942 593 1874 1559 <0.001
Per cent 11.5 1.2 1.5 1.5 1.3
The data includes the calendar years 2004–2010.
*ICD-10 codes C15-C26, D12 and K00-K93.
Figure 1 Number of colonoscopies per individual in the
Finnish colorectal cancer screening trial in 2004–2010 by arm.
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Limitations of the study
One limitation of the study is the lack of primary care
data. Resources used at the primary healthcare level,
either by the screening or the control groups, were not
registered at FHDR during the study years. Small munici-
palities with inadequate resources refer patients to hos-
pital for the primary colonoscopy. Other municipalities
have their own endoscopy units and their primary colon-
oscopies are not included in our data. In both cases, if
any further examination or treatment (eg, removal of
large polyps, suspicious cancer) is necessary, the patient
is referred to the secondary healthcare. From earlier
work,2 we know that 90% of the test-positives complied
to colonoscopy, which means that approximately 2650
primary colonoscopies should be added to the ﬁgures of
the screening group reported here. However, the lack of
data on primary healthcare concerns both, and no com-
prehensive data are available on possible colonoscopies
or other diagnostics at the primary healthcare level in
the control group or non-attenders. According to
national care guidelines,21 the primary investigation for
symptomatic patients is endoscopy (not FOBT) and thus
controls also have access to primary care endoscopy. The
difference in use of primary healthcare services between
the two groups can only be speculated, but it is likely
that the proportional differences based on FHDR data
should indicate any overall differences.
A major concern in FOBT screening and resource use
has been the possible increase in the number of diag-
nostic procedures, mainly colonoscopies, and our study
conﬁrms this. In the UK, Price et al22 reported an
increase of 21–31% in the number of hospital colonos-
copies due to FOBT screening, but a simultaneous
increase was also seen in the demand for symptom-based
colonoscopies. In Australia, it has been estimated that a
biennial FOBT would result in ﬁve times more colonos-
copies than the option of no screening.23 In our study, a
total of 930 more hospital colonoscopies were con-
ducted for the screening group than for the control
group, resulting in a 53% increase in hospital colonos-
copies. The proportion of people with at least one col-
onoscopy was slightly higher in the screening group
than in the control group (1.5% vs 1.3%). In particular,
patients with a positive FOBT result seemed to increase
the probability of hospital resource use, including colon-
oscopies, compared to those with a negative FOBT or to
those who did not attend the screening. This implies
that an abnormal ﬁnding in the screening results in a
number of colonoscopies while without screening, the
control group will receive only one diagnostic colonos-
copy based on the symptoms, without FOBT.
Based on the present study, it is, however, impossible
to say whether the increase is only temporary. For
example, Thiis-Evensen et al24 showed that, with a 9-year
observation period after a screening colonoscopy, the
screening group had 50% fewer usual-care distal endo-
scopic examinations than the control group.
Furthermore, Seeff et al25 have argued that if all of the
potential endoscopic capacity existing in the USA was
used for organised colorectal cancer screening, the
unscreened population could be screened within 1 year
using the FOBT and colonoscopy for those with a posi-
tive test result. For example, follow-up after polypectomy
is carried out at more frequent intervals than recom-
mended. In comparison, many published estimates of
colonoscopies in cost-effectiveness analyses are reported
only for different screening strategies, while the alterna-
tive of ‘no systematic screening’ is often left out or
assumed to be zero.11 12 26
Our screening interval was 2 years. After that, the con-
founding effect of the second screen is introduced, pre-
suming that the effects of the ﬁrst and second round are
different. In the Finnish CRC screening programme,
everyone in the screening group will receive an invita-
tion to screening also during the second round, regard-
less of the screening result in the ﬁrst round. The long
term evaluation is thus not that straightforward and may
include a source of bias.
In conclusion, colorectal cancer screening using the
FOBT seems to slightly increase the volume of hospital
outpatient visits, inpatient episodes and hospital colonos-
copies in Finland.
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